Novo-Nordisk stock reports 25% study weight loss pre-market
Published on 10/21/2026 at 08:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSStudy findings and pre-market
- Novo Nordisk reported study data showing 25% average weight loss on October 20, 2026.
- The evaluation covered 68 weeks and about 2,300 overweight women.
- Novo-Nordisk stock trades pre-market at EUR 35.00 at 8:43 a.m. CEST at Lang & Schwarz on October 21, 2026.
Novo Nordisk reported new CagriSema study data on October 20, 2026, according to Markets Insider. Novo-Nordisk stock trades pre-market at EUR 35.00 at 8:43 a.m. CEST at Lang & Schwarz on October 21, 2026.
CagriSema study data
The evaluation found average weight loss of 25% among about 2,300 overweight women after 68 weeks of treatment. The placebo group recorded average weight loss of 3%. The report also said the study's final results showed average weight loss of 22.7% among adults after 68 weeks, with CagriSema linked to reduced abdominal fat. Markets Insider reported the findings.
Ahead of the Xetra open
The pre-market indication was recorded at 8:43 a.m. CEST. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Novo Nordisk stock.
The group and its market
Novo Nordisk develops medicines for healthcare markets. The company’s CagriSema program combines semaglutide and cagrilintide as a weight-loss treatment, according to Markets Insider.
Market context: Latest market reports.
